Article
Clinical Neurology
Anuschka Silva-Spinola, Marisa Lima, Maria Joao Leitao, Catarina Bernardes, Joao Duraes, Diana Duro, Miguel Tabuas-Pereira, Isabel Santana, Ines Baldeiras
Summary: This study evaluated the potential of peripheral neurological biomarkers to predict progression to Alzheimer's disease in patients with mild cognitive impairment (MCI), and examined the relationship between blood and cerebrospinal fluid (CSF) markers. The results showed that levels of NfL, GFAP, and p-Tau181 in the blood were significantly higher in patients who progressed to Alzheimer's disease. Combining blood-based GFAP, NfL, and p-Tau181 may serve as a prognostic tool for MCI.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Review
Medicine, Research & Experimental
Antoine Leuzy, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Shorena Janelidze, Jeffrey L. Dage, Oskar Hansson
Summary: Blood-based biomarkers are playing an increasing role in the diagnosis and research of neurodegenerative disorders like Alzheimer's disease. Biomarkers such as plasma P-tau and NfL show promising potential for detection and monitoring of these diseases.
EMBO MOLECULAR MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Ling Wu, Nailya Gilyazova, John F. Ervin, Shih-Hsiu J. Wang, Bin Xu
Summary: Tau aggregates, a characteristic feature of tauopathies, can be differentiated and used as potential biomarkers using site-specific phospho-tau antibodies. We identified several novel phosphorylation sites and showed that p-tau198 is a promising AD biomarker that can also discriminate related tauopathies. Our work provides a new avenue for diagnosis and differentiation tools for AD and related tauopathies.
ACS CHEMICAL NEUROSCIENCE
(2022)
Article
Clinical Neurology
Koen Delmotte, Jolien Schaeverbeke, Koen Poesen, Rik Vandenberghe
Summary: This retrospective longitudinal study aimed to investigate the prognostic value of CSF-based ATN classification for cognitive decline in a clinical setting over a 3-year period. Results showed that ATN classification, as well as individual CSF biomarkers, had a significant correlation with future cognitive decline, with the Aβ(42)/t-tau ratio showing the highest correlation.
ALZHEIMERS RESEARCH & THERAPY
(2021)
Article
Immunology
Sarah A. Cooley, Brittany Nelson, Anna Boerwinkle, Kevin E. Yarasheski, Kris M. Kirmess, Matthew R. Meyer, Suzanne E. Schindler, John C. Morris, Anne Fagan, Beau M. Ances, Jane A. O'Halloran
Summary: The plasma amyloid-beta (A beta) 42/A beta 40 ratio, a blood-based biomarker for brain amyloid in Alzheimer disease, is not abnormal in older cognitively normal or cognitively impaired people with HIV.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Clinical Neurology
Gary A. Rosenberg
Summary: Binswanger disease is a type of vascular cognitive impairment and dementia. Biomarkers can aid in early diagnosis, such as using magnetic resonance imaging and cerebrospinal fluid or positron emission tomography to detect vascular disease-related proteins. Vascular disease accelerates cognitive decline, which is associated with misfolded proteins and inflammation. Early detection and treatment of dementia can be improved by advancements in plasma biomarker detection techniques and technologies like machine learning.
Review
Cell Biology
Jade Hawksworth, Esperanza Fernandez, Kris Gevaert
Summary: Alzheimer's disease, the most common form of dementia, lacks effective treatments and early diagnostic tools. Proteomic technologies have identified potential biomarkers for AD, and studies have focused on amyloid and tau proteins as well as proteins associated with neurodegeneration, neuroinflammation, lipid transport, and mitochondrial dysfunction.
AGEING RESEARCH REVIEWS
(2022)
Article
Neurosciences
Ana Catarina Rodrigues-Neves, Rafael Carecho, Sonia Catarina Correia, Cristina Carvalho, Elisa Juliao Campos, Filipa Isabel Baptista, Paula Isabel Moreira, Antonio Francisco Ambrosio
Summary: At the early stages of Alzheimer's disease pathology, the retina, hippocampus, and cortex are not significantly affected but already present some molecular and cellular alterations. The retina did not mirror the changes detected in the brain, and these observations should be taken into account when using the retina as a potential diagnostic tool for AD.
MOLECULAR NEUROBIOLOGY
(2021)
Article
Chemistry, Applied
Naila Sher, Mushtaq Ahmed, Nadia Mushtaq, Rahmat Ali Khan
Summary: In this study, silver nanoparticles were synthesized using the herbal extract of Hippeastrum hybridum L. plant. These nanoparticles exhibited significant potential in inhibiting acetylcholinesterase activity, making them a potential herbal source for the treatment of Alzheimer's disease.
APPLIED ORGANOMETALLIC CHEMISTRY
(2023)
Review
Chemistry, Analytical
Xingyun Liu, Yibiao Liu, Qiong Liu
Summary: Alzheimer's disease (AD) is a neurodegenerative disease characterized by memory loss and cognitive impairment. Early diagnosis is crucial for intervention and treatment effectiveness assessment, but current clinical methods are costly and inaccessible. Blood sample detection offers a less invasive and more accessible alternative, with various assays developed for the detection of AD biomarkers. Fluorescence-sensing techniques, with their low toxicity and high sensitivity, can not only detect biomarker levels in blood but also image them in the brain in real time. This review summarizes the recent development of fluorescent sensing platforms and their potential clinical applications.
Article
Clinical Neurology
Claudiaf Cicognola, Shorena Janelidze, Joakim Hertze, Henrik Zetterberg, Kaj Blennow, Niklas Mattsson-Carlgren, Oskar Hansson
Summary: Plasma GFAP can detect AD pathology in patients with MCI and predict conversion to AD dementia, showing potential clinical utility.
ALZHEIMERS RESEARCH & THERAPY
(2021)
Review
Cell Biology
Ajay Elangovan, Harysh Winster Suresh Babu, Mahalaxmi Iyer, Abilash Valsala Gopalakrishnan, Balachandar Vellingiri
Summary: Amyloid precursor protein profusion in Trisomy 21, also called Down Syndrome (DS), is linked to the genetic determination of Alzheimer's disease (AD). Due to improvements in patient care, the life expectancy of DS patients has increased, resulting in a higher chance of developing AD, which then leads to the formation of plaques and tangles in the brain and subsequent dementia. Genetic changes in Trisomy 21 cause cellular dysfunction, including impaired autophagy, mitochondrial and lysosomal dysfunction, and copy number variation. This article reviews the cognitive impairment and mechanisms underlying DS-AD conditions and discusses recent findings on biomarkers and therapeutics for DS-AD.
AGEING RESEARCH REVIEWS
(2023)
Article
Clinical Neurology
Danielle Beckman, Paramita Chakrabarty, Sean Ott, Amanda Dao, Eric Zhou, William G. Janssen, Kristine Donis-Cox, Scott Muller, Jeffrey H. Kordower, John H. Morrison
Summary: This study successfully simulated tau protein misfolding and propagation similar to humans in rhesus monkeys, along with observing biomarkers of neuroinflammation and neuronal loss. These findings provide hope for the development of new therapies for AD.
ALZHEIMERS & DEMENTIA
(2021)
Article
Clinical Neurology
Hao Hu, Li Meng, Yan-Lin Bi, Wei Zhang, Wei Xu, Xue-Ning Shen, Ya-Nan Ou, Ya-Hui Ma, Qiang Dong, Lan Tan, Jin-Tai Yu
Summary: This study revealed associations between blood pressure and cognition, with mid-life hypertension and late-life lower diastolic BP being linked to cognitive impairment. Tau pathologies were found to play crucial roles in the relationship between blood pressure and cognition, independent of amyloid pathology.
ALZHEIMERS & DEMENTIA
(2022)
Article
Geriatrics & Gerontology
Julia B. Libby, Mabel Seto, Omair A. Khan, Dandan Liu, Vlad Petyuk, Nekesa C. Oliver, Min Ji Choi, Marsalas Whitaker, Khiry L. Patterson, Albert B. Arul, Katherine A. Gifford, Kaj Blennow, Henrik Zetterberg, Logan Dumitrescu, Rena A. S. Robinson, Angela L. Jefferson, Timothy J. Hohman
Summary: This study explored the associations between gene expression of VEGF family members in blood and cognitive performance and AD pathology. The results showed that higher blood gene expression of PGF was associated with faster memory decline, higher blood protein abundance of FLT4 was associated with lower amyloid and tau pathology, and higher blood gene expression of VEGFB was associated with better baseline memory. Furthermore, higher blood gene expression of VEGFB was associated with lower brain expression of VEGFB.
NEUROBIOLOGY OF AGING
(2023)
